Therefore, we conducted a meta-analysis of this randomized controlled trials (RCTs) to determine the effects of SGLT2 inhibitors on eGFR, UACR and AKI compared to with placebo or other antidiabetic treatments in patients with T2DM and CKD. This evidence concerns the gene SLC5A2 and acute kidney injury.